Zobrazeno 1 - 10
of 509
pro vyhledávání: '"Fairooz, F."'
Autor:
Margalit, Ofer, Harmsen, William S., Shacham-Shmueli, Einat, Voss, Molly M., Boursi, Ben, Wagner, Anna D., Cohen, Romain, Olswold, Curtis L., Saltz, Leonard B., Goldstein, Daniel A., Hurwitz, Herbert, Tebbutt, Niall C., Kabbinavar, Fairooz F., Adams, Richard A., Chibaudel, Benoist, Grothey, Axel, Yoshino, Takayuki, Zalcberg, John, de Gramont, Aimery, Shi, Qian, Lenz, Heinz-Josef
Publikováno v:
In European Journal of Cancer January 2023 178:162-170
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kareem, Fairooz F.1 cenderlla78@yahoo.com, Saeed, Asrar A.1, Al-Kadhemy, Mahasin F.1, Kadhum, Farah J.1
Publikováno v:
Kuwait Journal of Science. Jul2023, Vol. 50 Issue 3B, p237-246. 10p.
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186a6cc4f094b6d28c76ddac63f92a21
https://doi.org/10.1200/jco.22.02543
https://doi.org/10.1200/jco.22.02543
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Margalit, Ofer, Harmsen, William S., Shacham-Shmueli, Einat, Voss, Molly M., Boursi, Ben, Wagner, Anna D., Cohen, Romain, Olswold, Curtis L., Saltz, Leonard B., Goldstein, Daniel A., Hurwitz, Herbert, Tebbutt, Niall C., Kabbinavar, Fairooz F., Adams, Richard A., Chibaudel, Benoist, Grothey, Axel, Yoshino, Takayuki, Zalcberg, John, de Gramont, Aimery, Shi, Qian, Lenz, Heinz-Josef
Publikováno v:
In European Journal of Cancer November 2023 194
Autor:
Sara A. Hurvitz, Maureen E. Trudeau, William J. Gradishar, Larisa Ryvo, Ming-Shen Dai, Sujith Kalmadi, Cristiano Souza, Eduardo Cronemberger, Suzette Delaloge, Adam Brufsky, Mafalda Oliveira, Vladimir Milovanov, Beverly Moy, Sung Bae Kim, Kiana Keyvanjah, J. Alarcón, Fairooz F. Kabbinavar, Ron Bose, Richard A. Bryce, Cristina Saura, Judith Bebchuk, Barbara Haley, Luciana Landeiro
Publikováno v:
The Oncologist
The oncologist, vol 26, iss 8
Scientia
The oncologist, vol 26, iss 8
Scientia
Background Neratinib has efficacy in central nervous system (CNS) metastases from HER2‐positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capeci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aa5727188c0b770c145eea2ece9e133
http://europepmc.org/articles/PMC8342591
http://europepmc.org/articles/PMC8342591
Autor:
Kabbinavar, Fairooz F., Flynn, Patrick J., Kozloff, Mark, Ashby, Mark A., Sing, Amy, Barr, Charles E., Grothey, Axel
Publikováno v:
In European Journal of Cancer May 2012 48(8):1126-1132
Autor:
Kroeger, Nils, Rampersaud, Edward N., Patard, Jean-Jacques, Klatte, Tobias, Birkhäuser, Frédéric D., Shariat, Shahrokh F., Lang, Hervé, Rioux-Leclerq, Nathalie, Remzi, Mesut, Zomorodian, Nazy, Kabbinavar, Fairooz F., Belldegrun, Arie S., Pantuck, Allan J. †
Publikováno v:
In The Journal of Urology 2012 187(2):418-423
Autor:
Einat S Shmueli, Morteza Raeisi, Benoist Chibaudel, Herbert Hurwitz, Leonard B. Saltz, Fairooz F. Kabbinavar, Niall C. Tebbutt, Axel Grothey, Richard Adams, John Raymond Zalcberg, Takayuki Yoshino, Jean-Baptiste Bachet, Romain Cohen, Lama Sharara, Thierry Andre, Qian Shi, Aimery De Gramont
Publikováno v:
Journal of Clinical Oncology. 41:118-118
118 Background: Anti-VEGF is widely used in the treatment (trt) of metastatic colorectal cancer (mCRC). Only studies with bevacizumab (BEV) have shown survival benefit (bnf) in first line trt. The magnitude of bnf might differ based on the metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::075bf270d5824f640b34b522fbdddd7c
https://doi.org/10.1200/jco.2023.41.4_suppl.118
https://doi.org/10.1200/jco.2023.41.4_suppl.118